Comparative Pharmacology
Head-to-head clinical analysis: SOMOPHYLLIN DF versus THEOCLEAR 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOMOPHYLLIN DF versus THEOCLEAR 100.
SOMOPHYLLIN-DF vs THEOCLEAR-100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and blocking adenosine receptors.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors.
Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/mL.
100 mg orally every 6 hours; adjust based on serum theophylline concentrations and clinical response (target 5-15 mcg/mL).
None Documented
None Documented
Terminal elimination half-life: 3–12 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours), congestive heart failure, and in neonates; also prolonged in elderly and patients with fever or viral illness. Half-life is shorter in smokers (4–5 hours).
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In smokers, half-life is reduced by 50%; in patients with hepatic cirrhosis or heart failure, half-life is prolonged to 24-36 hours.
Renal excretion of unchanged drug: approximately 10%; hepatic metabolism accounts for >90% of elimination; metabolites are excreted renally. Less than 5% eliminated in feces.
Renal excretion accounts for approximately 10% of the administered dose as unchanged drug. The remainder is hepatically metabolized, with metabolites excreted renally. Biliary/fecal elimination is negligible (<5%).
Category C
Category C
Bronchodilator
Bronchodilator